Apparent declining efficacy in randomized trials: Examples of the Thai RV144 HIV vaccine and South African CAPRISA 004 microbicide trials

AIDS

Volumn 26, Issue 2, 2012, Pages 123-126

  O'Hagan, Justin J ^a,b   Hernán, Miguel A ^a,c   Walensky, Rochelle P ^d,e,f   Lipsitch, Marc ^a,b  

^a Department of Epidemiology ^*  (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c HARVARD MIT DIVISION OF HEALTH SCIENCES AND TECHNOLOGY   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

bias; clinical trial; HIV; prevention

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; NOTE; OUTCOMES RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SOUTH AFRICA; THAILAND; VACCINATION;

AIDS VACCINES; HIV INFECTIONS; HUMANS; IMMUNIZATION PROGRAMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SOUTH AFRICA; THAILAND;

EID: 84155163938     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32834e1ce7     Document Type: Note

References (43)

1. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361:2209-2220.
2. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010; 329:1168-1174.
3. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010; 363:2587-2599.
4. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365:493-505.
5. Centers for Disease Control Prevention TDF2 Press Release. http://www.cdc.gov/nchhstp/newsroom/PrEPHeterosexuals. html. [Accessed 20 July 2011].
6. PartnersinPreventionPrEPPressRelease.http://depts.washington. edu/uwicrc/research/studies/files/PrEP-PressRelease-UW-13Jul 2011.pdf. [Accessed 20 July 2011].
7. Michael N. RV 144 update: vaccination with ALVAC and AIDSVAX to prevent hiv-1 infection in thai adults. 17th conference on retroviruses & opportunistic infections, (2010). http:// app2.capitalreach.com/esp1204/servlet/ tc?c=10164&cn= retro&e=12354&m=1&s=20431&&espmt= 2&3file = 12354&m4bfile=12354. [Accessed 13 October 2010].
8. Abdool Karim Q. Safety and effectiveness of 1% tenofovir vaginal microbicide gel in south african women: results of the CAPRISA 004 trial. AIDS 2010: XVIII International AIDS Conference, (2010). http://globalhealth.kff.org/ AIDS2010/July-20/Safety-and-Effectiveness.aspx. [Accessed 3 November 2010].
9. Lagakos SW, Schoenfeld DA. Properties of proportionalhazards score tests under misspecified regression models. Biometrics 1984; 40:1037-1048.
10. Gail MH, Wieand S, Piantadosi S. Biased estimates of treatment effect in randomized experiments with nonlinear regressions and omitted covariates. Biometrika 1986; 71:431-444.
11. Vaupel JW, Manton KG, Stallard E. The impact of heterogeneity in individual frailty on the dynamics of mortality. Demography 1979; 16:439-454.
12. Vaupel JW, Yashin AI. Heterogeneity's ruses: some surprising effects of selection on population dynamics. Am Stat 1985; 39:176-185.
13. Yashin AI, Iachine IA. How frailty models can be used for evaluating longevity limits: taking advantage of an interdisciplinary approach. Demography 1997; 34:31-48.
14. Govindarajulu US, Lin H, Lunetta KL, D'Agostino RB Sr. Frailty models: applications to biomedical and genetic studies. Stat Med 2011; 30:2754-2764.
15. Hernán MA. The hazards of hazard ratios. Epidemiology 2010; 21:13-15.
16. Hernán MA, Hernández-Díaz S, Robins JM. A structural approach to selection bias. Epidemiology 2004; 15:615-625.
17. Rothman KJ, Greenland S, Lash TL. Modern epidemiology, 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2008.
18. Arrighi HM, Hertz-Picciotto I. The evolving concept of the healthy worker survivor effect. Epidemiology 1994; 5:189-196.
19. Moride Y, Abenhaim L, Yola M, Lucein A. Evidence of the depletion of susceptibles effect in nonexperimental pharmacoepidemiologic research. J Clin Epidemiol 1994; 47:731-737.
20. Cox DR. Regression models and life-tables. J R Stat Soc Series B Methodol 1972; 34:187-220.
21. Boutitie F, Gueyffier F, Pocock SJ, Boissel JP. Assessing treatment-time interaction in clinical trials with time to event data: a meta-analysis of hypertension trials. Stat Med 1998; 17:2883-2903.
22. Bassler D, Briel M, Montori VM, Lane M, Glasziou P, Zhou Q, et al. Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis. JAMA 2010; 303:1180-1187.
23. Bassler D, Ferreira-Gonzalez I, Briel M, Cook DJ, Devereaux PJ, Heels-Ansdell D, et al. Systematic reviewers neglect bias that results from trials stopped early for benefit. J Clin Epidemiol 2007; 60:869-873.
24. Montori VM, Devereaux PJ, Adhikari NKJ, Burns KEA, Eggert CH, Briel M, et al. Randomized trials stopped early for benefit: a systematic review. JAMA 2005; 294:2203-2209.
25. Pocock S, White I. Trials stopped early: too good to be true? Lancet 1999; 353:943-944.
26. Graham SM, Shah PS, Aesch ZC-von, Beyene J, Bayoumi AM. A systematic review of the quality of trials evaluating biomedical HIV prevention interventions shows that many lack power. HIV Clin Trials 2009; 10:413-431.
27. Padian NS, McCoy SI, Balkus JE, Wasserheit JN. Weighing the gold in the gold standard: challenges in HIV prevention research. AIDS 2010; 24:621-635.
28. Hayes R, Kapiga S, Padian N, McCormack S, Wasserheit J. HIV prevention research: taking stock and the way forward. AIDS 2010; 24 (Suppl 4):S81-S92.
29. Gray RH. Methodologies for evaluating HIV prevention intervention (populations and epidemiologic settings). Curr Opin HIV AIDS 2009; 4:274-278.
30. Auvert B, Sitta R, Zarca K, Mahiane SG, Pretorius C, Lissouba P. The effect of heterogeneity on HIV prevention trials. Clin Trials 2011; 8:144-154.
31. Ford I, Norrie J, Ahmadi S. Model inconsistency, illustrated by the Cox proportional hazards model. Stat Med 1995; 14:735-746.
32. Hauck WW, Anderson S, Marcus SM. Should we adjust for covariates in nonlinear regression analyses of randomized trials? Control Clin Trials 1998; 19:249-256.
33. Hernández AV, Eijkemans MJ, Steyerberg EW. Randomized controlled trials with time-to-event outcomes: how much does prespecified covariate adjustment increase power? Ann Epidemiol 2006; 16:41-48.
34. Celum C, Wald A, Lingappa JR, Magaret AS, Wang RS, Mugo N, et al. Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med 2010; 362: 427-439.
35. Weller S, Davis K. Condom effectiveness in reducing heterosexual HIV transmission. Cochrane Database Syst Rev 2002; 1:CD003255.
36. Warner L, Newman DR, Austin HD, Kamb ML, Douglas JM Jr, Malotte CK, et al. Condom effectiveness for reducing transmission of gonorrhea and chlamydia: the importance of assessing partner infection status. Am J Epidemiol 2004; 159:242-251.
37. Niccolai LM, Rowhani-Rahbar A, Jenkins H, Green S, Dunne DW. Condom effectiveness for prevention of Chlamydia trachomatis infection. Sex Transm Infect 2005; 81:323-325.
38. Warner L, Ghanem KG, Newman DR, Macaluso M, Sullivan PS, Erbelding EJ. Male circumcision and risk of HIV infection among heterosexual African American men attending Baltimore sexually transmitted disease clinics. J Infect Dis 2009; 199:59-65.
39. Longini IM, Halloran ME. A frailty mixture model for estimating vaccine efficacy. J R Stat Soc Ser C Appl Stat 1996; 45:165-173.
40. Halloran ME, Longini IM, Struchiner CJ. Estimability and interpretation of vaccine efficacy using frailty mixing models. Am J Epidemiol 1996; 144:83-97.
41. Haber M, Ndikuyeze A. Estimation of individual and population vaccination effectiveness from time-to-event data. Stat Med 1998; 17:2617-2623.
42. Yang Y, Gilbert P, Longini IM, Halloran ME. A bayesian framework for estimating vaccine efficacy per infectious contact. Ann Appl Stat 2008; 2:1409-1431.
43. Cole SR, Hernán MA. Adjusted survival curves with inverse probability weights. Comput Methods Programs Biomed 2004; 75:45-49.